In December 2009, MD Anderson reported promising results with Incyte. Dr Verstovsek, MD, PhD stated, "This [Incycte] study continues to demonstrate that JAK1/2 inhibition can lead to rapid clinical benefits in myelofibrosis patients, including unprecedented reductions in splenomegaly which affects the majority of these patients. We have also seen impressive and clinically meaningful reductions in fatigue, night seats and pruritus, as well as increased appetite and weight gain in the majority of treated patients - all of which are important improvements in their clinical condition." Click here to read the full text of the Incycte press release from June 2009 and the press release from December 2009.

Read more about JAK2:

JAK2: Fast facts
JAK2: Your questions answered
Research papers

You can learn much more about the JAK2 inhibitor trials from several organisations in the United States. The MPD Foundation raises funds for MPD research and reports on clinical trials, press releases from biotech and pharmaceutical companies and the latest discoveries. You can also learn about open clinical trials in the United States from the National Institutes of Health (NIH) and the National Cancer Institute (NCI)'s websites.